Dr. Hurdle’s research centers on the discovery of novel approaches to treat antibiotic-resistant infections and elucidating molecular and physiological responses of bacteria to antimicrobials. Hurdle’s laboratory adopts a multi-disciplinary approach, involving: discovery of novel antimicrobials through phenotypic and enzyme-based screening of chemical libraries; characterizing the molecular action of novel antimicrobials; assessing antibiotic efficacy in animal models of disease; and interrogating the impact of genetic resistance on bacterial physiology and virulence. Notable achievements include the discovery of antimicrobial agents that are at various pre-clinical stages for treating Clostridium difficile infection, biofilm-mediated infections and Mycobacterium tuberculosis. A key concept from Hurdle’s research is that the bacterial membrane is an Achilles of recalcitrant bacteria, such as stationary phase cells and biofilms; these cell types display phenotypic resistance and cause infections to relapse after treatment. Through this concept, we are probing mechanisms of chemically induced cell death in C. difficile. We collaborate closely with medicinal chemists, structural biologists and pharmacologists, to achieve our goal of translating discoveries to human medicine.